Drug Profile
Labetuzumab Y-90
Alternative Names: 90Y-hMN14; Anti-CEA monoclonal antibody MN 14-Y-90; CEA-Cide-Y-90; hCEA-Y-90; hMN14; IMMU-101Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Immunomedics
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Pancreatic cancer
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 23 Jun 2004 Immunomedics has completed two phase I trials in colorectal and pancreatic cancers in the US
- 23 Apr 2002 Phase-I/II clinical trials in Colorectal cancer in USA (IV-infusion)